+0.0829  (+3.65%)
Volume (24h): 665.04K Day Range: 2.13 - 2.45
Market Cap: 74.57M 52W Range: 0.2311 - 7.03
Mar-24-20 12:17PM Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry LeadersBusiness Wire
Mar-23-20 12:17PM Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science ExecutivesBusiness Wire
Mar-05-20 01:05PM Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video InterviewBusiness Wire
Mar-04-20 01:00PM Genprex to Present at the 2020 LD Micro Virtual ConferenceACCESSWIRE
Mar-03-20 01:17PM Genprex to Present at the 2020 LD Micro Virtual ConferenceBusiness Wire
Feb-21-20 09:15PM Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without WarrantsBusiness Wire
Feb-20-20 03:22PM Those Golden
Feb-19-20 02:23PM Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without WarrantsBusiness Wire
01:05PM Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPXBenzinga
Feb-11-20 01:17PM Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for DiabetesBusiness Wire
Feb-06-20 01:17PM Genprex Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness Wire
Feb-05-20 02:00PM Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)Business Wire
Feb-03-20 01:17PM Genprex to Present at NobleCon16 Investor ConferenceBusiness Wire
Jan-29-20 01:18PM Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer TherapyBusiness Wire
Jan-28-20 01:00PM Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock OfferingBusiness Wire
Jan-24-20 12:00PM Genprex: The Bad and the Good of Capital
Jan-23-20 02:00PM Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-MarketBusiness Wire
Jan-22-20 03:54PM Genprex's stock rallies on FDA fast-track designationMarketWatch
Jan-21-20 01:00PM Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung CancerBusiness Wire
Jan-06-20 01:00PM Genprex to Present at Biotech Showcase™ 2020 in San FranciscoBusiness Wire
Nov-20-19 04:15PM Genprex Announces $1.26 Million Registered Direct OfferingBusiness Wire
Nov-19-19 01:00PM Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung CancersBusiness Wire
Nov-04-19 01:00PM Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness MonthBusiness Wire
Oct-15-19 12:00PM MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019ACCESSWIRE
Oct-09-19 12:00PM Genprex to Present at the MicroCap Rodeo Investor ConferenceBusiness Wire
Oct-07-19 12:00PM Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry SupportBusiness Wire
Sep-26-19 12:30PM Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer TreatmentGlobeNewswire
Sep-25-19 12:30PM Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer TreatmentsGlobeNewswire
Sep-18-19 12:00PM Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019Business Wire
Sep-11-19 12:00PM Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast CancerBusiness Wire
Sep-07-19 08:35PM CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceBusiness Wire
Sep-06-19 12:30PM Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy TreatmentsGlobeNewswire
Sep-04-19 05:43PM Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate DeckBusiness Wire
Aug-23-19 12:30PM Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech SectorGlobeNewswire
Aug-22-19 12:30PM Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone AchievementsGlobeNewswire
Aug-21-19 07:31PM What Kind Of Investor Owns Most Of Genprex, Inc. (NASDAQ:GNPX)?Simply Wall St.
Genprex, Inc., a clinical-stage gene therapy biotechnology company, develops immunogene therapy products for treating cancer. Its lead drug candidate is Oncoprex, which is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also conducting preclinical research for developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)